

Clinical trials of ixmyelocel-T

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
ixmyelocel-T vs control			
Catheter-DCM , 2014 [NCT01020968] n=NA follow-up:	-	patients with dilated cardiomyopathy	
IMPACT-DCM , 2014 [NCT00765518] n=NA follow-up:	-	patients with dilated cardiomyopathy	
ixmyelocel-T vs placebo			
ixCELL-DCM , 2016 [NCT01670981] n=60/66 follow-up:	ixmyelocel-T versus placebo	patients with New York Heart Association class III or IV symptomatic heart failure due to ischaemic dilated cardiomyopathy, who had left ventricular ejection fraction 35% or less, an automatic implantable cardioverter defibrillator, and who were ineligible for revascularisation procedures	

More details and results :

- cell-based therapies for heart failure in all types of patients at <http://www.trialresultscenter.org/go-Q515>
- regenerative therapy for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q649>

References

Catheter-DCM, 2014:

Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 2014;115:730-7 [25142002]

IMPACT-DCM, 2014:

Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 2014 Sep 26;115:730-7 [25142002]

ixCELL-DCM, 2016:

Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. *Lancet* 2016;: [27059887]